Version history

{
  "session_id": "sess_SDA-BIOMNI-POLYGENI-b3028c7a",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "mini-max",
  "action": "propose",
  "content": "\n\n# Novel Hypotheses: AD PRS Prediction & Rare Variant Integration\n\n---\n\n## Hypothesis 1: Rare Variant Burden Acts as an Effect Modulator on PRS Threshold Effects\n\n**Description:** Individuals carrying pathogenic rare variants in high-penetrance AD genes (APP, PSEN1, PSEN2) will demonstrate a significantly lower PRS required to reach clinical threshold, suggesting a multiplicative rather than additive genetic model. The mechanistic basis involves shared downstream effects on amyloid processing—rare variants create a \"functional deficit\" that lowers the polygenic burden needed to exceed the pathogenicity threshold, analogous to a \"first hit\" paradigm.\n\n**Target:** Effect modification between APP/PSEN1/PSEN2 rare variants and polygenic amyloid pathway SNPs\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 2: Age-of-Onset Stratification Reveals PRS Performance Nonlinearity\n\n**Description:** PRS predictive accuracy will demonstrate a U-shaped relationship across age decades, with peak discrimination in early-onset AD (60-65) and late-onset (>85), but decreased accuracy in the 70-80 age range due to competing non-genetic risk factors (vascular, metabolic). Early-onset cases represent \"genetic load\" extremes where polygenic burden is highest, while extreme late-onset may reflect neuroprotective polygenic backgrounds that PRS captures effectively.\n\n**Target:** Age-dependent PRS calibration; candidate genes APOE, CLU, PICALM pathway\n\n**Confidence:** 0.68\n\n---\n\n## Hypothesis 3: Ancestry-Specific PRS Architecture Dissociation from European-Trained Models\n\n**Description:** PRS trained exclusively on European ancestry cohorts will demonstrate systematic failure in African ancestry populations—not due to LD structure differences, but because AD genetic architecture itself varies by ancestry through differential selective pressures on lipid metabolism genes (ABCA7, ABCA1). African ancestry-specific rare variants in lipid transport genes interact with a distinct polygenic background, requiring a separate PRS model that incorporates ancestry-matching rare variant burden at pathway level.\n\n**Target:** ABCA7, APOE, CLU regional ancestry-specific burden\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 4: Conditional Rare Variant Burden Improves PRS by Capturing Oligogenic Architecture\n\n**Description:** Current PRS ignores linkage disequilibrium with rare causal variants (e.g., ABCA7 nonsense variants in linkage with proxy SNPs). A conditional model incorporating rare variant burden scores alongside PRS will significantly improve variance explained by identifying individuals where GWAS signals actually tag rare variant carriers rather than capturing true polygenic signal. This is mechanistically distinct from simple additive models because rare variants and polygenic scores operate through partially overlapping but separable biological pathways.\n\n**Target:** ABCA7, TREM2, SORL1 rare variant detection; LD-tagging resolution\n\n**Confidence:** 0.70\n\n---\n\n## Hypothesis 5: Synaptic and Immune Pathway PRS Subscores Exhibit Stage-Specific Accuracy\n\n**Description:** PRS weighted toward microglial/immune pathways (INPP5D, SPI1, PLCG2) will predict conversion from MCI to AD with greater accuracy than amyloid-pathway-weighted PRS, because immune-mediated neurodegeneration represents a downstream convergence point more closely tied to clinical progression than upstream amyloidogenesis. Conversely, amyloid-pathway PRS will better predict underlying amyloid burden at preclinical stages.\n\n**Target:** Pathway-specific PRS decomposition; SPI1, INPP5D, PLCG2 immune modules vs. APP/PSEN amyloid module\n\n**Confidence:** 0.62\n\n---\n\n## Hypothesis 6: Polygenic Adaptation for Cognitive Reserve Masks True PRS-Disease Association\n\n**Description:** A subset of individuals with high AD PRS but preserved cognition carry polygenic variants in neuroprotective pathways (BDNF, COMT, NTRK2) that confer cognitive reserve, effectively \"canceling\" pathogenic polygenic burden. The mechanistic basis involves polygenic resilience alleles that upregulate synaptic plasticity genes, neurogenesis pathways, or mitochondrial efficiency—creating a genetic buffer against polygenic risk. Current PRS fails to capture this because it assumes additive pathogenic effects without resilience modifiers.\n\n**Target:** Cognitive reserve polygenic scores; BDNF, COMT, NTRK2 polygenic buffer effect\n\n**Confidence:** 0.58\n\n---\n\n## Hypothesis 7: Rare Variant Burden Combined with PRS Identifies a Distinct \"Metabolic\" AD Endophenotype\n\n**Description:** Integration of rare variants in glucose metabolism genes (IDE, AKT1, mTOR pathway genes) with PRS will identify a metabolic subtype of AD characterized by impaired brain glucose utilization preceding amyloid accumulation. This subtype will demonstrate differential PRS trajectory and reduced responsiveness to anti-amyloid therapies. Mechanistically, these cases represent metabolic failure driving neurodegeneration through energy deprivation rather than primary proteopathic seeds, explaining why PRS optimized for amyloid models underperforms.\n\n**Target:** IDE, AKT1, mTOR pathway rare variant integration; metabolic vs. amyloid subtypes\n\n**Confidence:** 0.55\n\n---\n\n### Priority Assessment\n\n| Hypothesis | Novelty | Mechanistic Clarity | Feasibility | Priority |\n|------------|---------|---------------------|-------------|----------|\n| H1 | High | High | Medium | ★★★★ |\n| H4 | High | High | High | ★★★★★ |\n| H5 | Medium | High | Medium | ★★★★ |\n| H2 | Medium | Medium | High | ★★★★ |\n| H3 | High | Medium | Medium | ★★★ |\n| H6 | High | Medium | Low | ★★★ |\n| H7 | High | Medium | Medium | ★★★ |\n\n**Recommended primary focus:** Hypothesis 4 (conditional rare variant integration) offers the clearest path to immediate methodological advancement, while Hypothesis 5 (pathway decomposition) provides translational utility for clinical stratification.",
  "tokens_used": "1471"
}